Skip to main content
Breaking News
Feature Story

Viral crossroads

BioCentury is providing in-depth analysis of the sudden impact of social media on difficult medical and ethical decisions surrounding compassionate access to experimental medicines. See the story from a multitude of angles in our continuing coverage.


Full Article
  • COVER STORY

    Unlocking cancer data

    With upfront buy-in from executive leadership in industry, academia and non-profits, Project Data Sphere for cancer could overcome challenges that have slowed other data-sharing efforts.

  • Blazing a path in data sharing

    The cancer data-sharing group Project Data Sphere met with the Critical Path Institute to learn from the institute's data-sharing initiatives for neurodegenerative diseases.

  • PRODUCT DISCOVERY & DEVELOPMENT

    Family resemblance

    Data reported so far for the most advanced PCSK9 inhibitors look similar, but trials in the LDL-lowering indications where the products will see the earliest uptake are still to come.

  • EMERGING COMPANY PROFILE

    Quantum: Silicon speed

    Quantum Biosystems has joined the single-molecule sequencing race with a solid-state system that could offer improved development timelines over nanopore technologies.

  • FINANCE

    Reasons Unknown

    Whatever caused Kenneth Moch to depart Chimerix as president and CEO, it wasn't stock performance.

  • Guest Commentary: Reducing the Burden

    In a Guest Commentary, two capital market veterans argue it is time to modify SEC disclosure rules that are not only a burden to young public biotechs, but do little to actually help investors.

  • Lean VC Profile

    Early backing from strategic investors and a string of deals like a new Celgene partnership have given Forma a free hand to build its drug discovery engine without leaning on VCs.

  • Ebb & Flow

    Deerfield's new crossover mandate. Nucana's B may be plenty. SkyPharma's debt riddance. Spinifex's U.S. beachhead. Also: Gilead; Biogen; Agios; Idenix; Puma; Adamas; Celladon, et al.

Today's Biotech & Pharma News

Compassionate Access

  • COVER STORY

    Contaminating cancer genomes

    Two European teams have pinpointed a DNA-protective enzyme as a chemically tractable target whose inhibition kills cancer cells by accelerating DNA damage. Both groups have identified small molecule inhibitors of the enzyme and are looking to partner with industry.

  • TRANSLATIONAL NOTES

    Translational tidbits

    AstraZeneca had a busy March, announcing five new public-private partnerships and launching its Open Innovation website to list additional partnership opportunities.

  • Expanding into new (bromo)domains

    The Neomed Institute has begun development of its first cancer therapeutic, a BRD4 inhibitor from Epigenetix that the not-for-profit organization thinks could have a selectivity advantage over competing molecules.

  • TARGETS & MECHANISMS

    Unfolding triple-negative breast cancer

    A team from Weill Cornell Medical College has found a unifying feature of triple-negative breast cancers -- overactivation of the transcription factor X-box binding protein 1. Blocking expression of the target decreases tumor formation and relapse in mice, but more druggable targets upstream of it might be better suited for further development.

  • THERAPEUTICS

    This Week in Therapeutics

    Inhibiting IL-17A or IL-23 to alleviate periodontitis; antagonizing KCNA3 to treat asthma; activating CD31 signaling to counter autoimmune and inflammatory conditions; and more...

  • TECHNIQUES

    This Week in Techniques

    Isoacyl dipeptides to increase insulin yield from chemical synthesis; binary nylon-3 copolymers containing cationic and hydrophobic subunits for antimicrobial activity; markers of distinct SHH-driven medulloblastomas; and more...

Subscribe Now
Free Trial

Preclinical Results

There were no items published for this section in the most recent issue. Click more >> to read previously published items.